HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Fundamental Analysis
USA - NASDAQ:HRMY - US4131971040 - Common Stock
33.39 USD
+0.08 (+0.24%)
33 USD
-0.39 (-1.17%)
Overall HRMY gets a fundamental rating of 8 out of 10. We evaluated HRMY against 192 industry peers in the Pharmaceuticals industry. HRMY gets an excellent profitability rating and is at the same time showing great financial health properties. An interesting combination arises when we look at growth and value: HRMY is growing strongly while it also seems undervalued. These ratings could make HRMY a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year HRMY was profitable.
HRMY had a positive operating cash flow in the past year.
HRMY had positive earnings in 4 of the past 5 years.
Of the past 5 years HRMY 4 years had a positive operating cash flow.
1.2 Ratios
HRMY's Return On Assets of 15.37% is amongst the best of the industry. HRMY outperforms 95.83% of its industry peers.
HRMY's Return On Equity of 22.23% is amongst the best of the industry. HRMY outperforms 92.71% of its industry peers.
Looking at the Return On Invested Capital, with a value of 17.20%, HRMY belongs to the top of the industry, outperforming 94.27% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HRMY is above the industry average of 13.48%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROIC | 17.2% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
1.3 Margins
The Profit Margin of HRMY (22.48%) is better than 92.19% of its industry peers.
In the last couple of years the Profit Margin of HRMY has grown nicely.
HRMY has a Operating Margin of 27.32%. This is amongst the best in the industry. HRMY outperforms 93.23% of its industry peers.
HRMY's Operating Margin has declined in the last couple of years.
HRMY's Gross Margin of 77.70% is amongst the best of the industry. HRMY outperforms 82.81% of its industry peers.
HRMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% |
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
HRMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, HRMY has more shares outstanding
Compared to 5 years ago, HRMY has less shares outstanding
The debt/assets ratio for HRMY has been reduced compared to a year ago.
2.2 Solvency
HRMY has an Altman-Z score of 5.15. This indicates that HRMY is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.15, HRMY is in the better half of the industry, outperforming 77.08% of the companies in the same industry.
The Debt to FCF ratio of HRMY is 0.57, which is an excellent value as it means it would take HRMY, only 0.57 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of HRMY (0.57) is better than 95.83% of its industry peers.
HRMY has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.18, HRMY is in line with its industry, outperforming 47.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Altman-Z | 5.15 |
ROIC/WACC1.92
WACC8.96%
2.3 Liquidity
A Current Ratio of 3.75 indicates that HRMY has no problem at all paying its short term obligations.
The Current ratio of HRMY (3.75) is comparable to the rest of the industry.
A Quick Ratio of 3.72 indicates that HRMY has no problem at all paying its short term obligations.
HRMY has a Quick ratio of 3.72. This is comparable to the rest of the industry: HRMY outperforms 59.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 50.71% over the past year.
HRMY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 44.61% yearly.
Looking at the last year, HRMY shows a very strong growth in Revenue. The Revenue has grown by 21.13%.
The Revenue has been growing by 160.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
3.2 Future
The Earnings Per Share is expected to grow by 34.90% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 14.35% on average over the next years. This is quite good.
EPS Next Y30.15%
EPS Next 2Y28.23%
EPS Next 3Y27.97%
EPS Next 5Y34.9%
Revenue Next Year18.42%
Revenue Next 2Y17.17%
Revenue Next 3Y15.73%
Revenue Next 5Y14.35%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.50, the valuation of HRMY can be described as very reasonable.
HRMY's Price/Earnings ratio is rather cheap when compared to the industry. HRMY is cheaper than 90.10% of the companies in the same industry.
When comparing the Price/Earnings ratio of HRMY to the average of the S&P500 Index (25.07), we can say HRMY is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 8.09, the valuation of HRMY can be described as reasonable.
HRMY's Price/Forward Earnings ratio is rather cheap when compared to the industry. HRMY is cheaper than 89.58% of the companies in the same industry.
HRMY is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.08, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.5 | ||
| Fwd PE | 8.09 |
4.2 Price Multiples
HRMY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HRMY is cheaper than 96.88% of the companies in the same industry.
HRMY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HRMY is cheaper than 93.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.47 | ||
| EV/EBITDA | 5.56 |
4.3 Compensation for Growth
HRMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HRMY may justify a higher PE ratio.
HRMY's earnings are expected to grow with 27.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y28.23%
EPS Next 3Y27.97%
5. Dividend
5.1 Amount
No dividends for HRMY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
33.39
+0.08 (+0.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.62%
Inst Owner Change-7.77%
Ins Owners0.52%
Ins Owner Change-104.37%
Market Cap1.92B
Revenue(TTM)825.94M
Net Income(TTM)185.68M
Analysts78.82
Price Target44.88 (34.41%)
Short Float %8.06%
Short Ratio4.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.77%
Min EPS beat(2)-11.17%
Max EPS beat(2)1.62%
EPS beat(4)3
Avg EPS beat(4)8.56%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)57.65%
EPS beat(12)9
Avg EPS beat(12)44.35%
EPS beat(16)12
Avg EPS beat(16)96.55%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-1%
Revenue beat(12)3
Avg Revenue beat(12)-0.86%
Revenue beat(16)5
Avg Revenue beat(16)-0.67%
PT rev (1m)-1.22%
PT rev (3m)-12.48%
EPS NQ rev (1m)-6.79%
EPS NQ rev (3m)-1.91%
EPS NY rev (1m)2.28%
EPS NY rev (3m)-3.02%
Revenue NQ rev (1m)0.7%
Revenue NQ rev (3m)0.78%
Revenue NY rev (1m)0.62%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.5 | ||
| Fwd PE | 8.09 | ||
| P/S | 2.33 | ||
| P/FCF | 6.47 | ||
| P/OCF | 6.45 | ||
| P/B | 2.3 | ||
| P/tB | 2.6 | ||
| EV/EBITDA | 5.56 |
EPS(TTM)3.18
EY9.52%
EPS(NY)4.13
Fwd EY12.36%
FCF(TTM)5.16
FCFY15.46%
OCF(TTM)5.17
OCFY15.49%
SpS14.36
BVpS14.52
TBVpS12.86
PEG (NY)0.35
PEG (5Y)N/A
Graham Number32.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROCE | 22.91% | ||
| ROIC | 17.2% | ||
| ROICexc | 54.26% | ||
| ROICexgc | 78.12% | ||
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% | ||
| FCFM | 35.95% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexgc growth 3Y-76.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 3% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 14.73 | ||
| Cash Conversion | 119.28% | ||
| Profit Quality | 159.9% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 | ||
| Altman-Z | 5.15 |
F-Score6
WACC8.96%
ROIC/WACC1.92
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
EPS Next Y30.15%
EPS Next 2Y28.23%
EPS Next 3Y27.97%
EPS Next 5Y34.9%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
Revenue Next Year18.42%
Revenue Next 2Y17.17%
Revenue Next 3Y15.73%
Revenue Next 5Y14.35%
EBIT growth 1Y17.58%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year36.94%
EBIT Next 3Y27.36%
EBIT Next 5Y22.83%
FCF growth 1Y75.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.68%
OCF growth 3Y30.64%
OCF growth 5YN/A
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a fundamental rating of 8 / 10 to HRMY.
Can you provide the valuation status for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.
Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.
What is the valuation of HARMONY BIOSCIENCES HOLDINGS based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 10.5 and the Price/Book (PB) ratio is 2.3.